The Wilson Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Wilson Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wilson Disease Market.
Some of the key takeaways from the Wilson Disease Pipeline Report:
- Companies across the globe are diligently working toward developing novel Wilson Disease treatment therapies with a considerable amount of success over the years.
- Wilson Disease companies working in the treatment market are Generation Bio, Deep genomics, Depymed Inc., Vivet therapeutics, Alexion, AstraZeneca, and others, are developing therapies for the Wilson Disease treatment
- Emerging Wilson Disease therapies in the different phases of clinical trials are- Research programme: gene therapies, DG 12P1, DPM-1001, VTX-801, ALXN1840, and others are expected to have a significant impact on the Wilson Disease market in the coming years.
- In October 2021, A multicenter, randomized, controlled, open-label, rater-blinded trial was started by Alexion Pharmaceuticals to compare the safety, pharmacokinetics, pharmacodynamics, and effectiveness of ALXN1840 to standard of treatment in pediatric Wilson Disease patients.
- In December 2020, A definite deal was reached by AstraZeneca and Alexion Pharmaceuticals for AstraZeneca to purchase Alexion. For every Alexion share, stockholders got $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca, which are represented by American Depositary Receipts (ADRs) as half of a single (1/2) ordinary share of AstraZeneca.
- Ultragenyx Pharmaceutical’s experimental AAV type 9 gene therapy, known as UX701, is intended to produce a stable expression of a shortened form of the ATP7B copper transporter after a single intravenous infusion. Preclinical research has demonstrated that the treatment improves the body’s distribution and excretion of copper and reverses the pathological signs and symptoms of Wilson liver disease. Right now, UX701 is in Phase I, II, and III.
Wilson Disease Overview
Excess copper is accumulated in many human tissues, including the liver, brain, and corneas of the eyes, which is the hallmark of Wilson’s disease. Wilson’s disease (WD) is a rare genetic ailment that usually manifests clinically in adolescence or the early 20s. It starts with liver dysfunction at age six.
Get a Free Sample PDF Report to know more about Wilson Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight
Emerging Wilson Disease Drugs Under Different Phases of Clinical Development Include:
- Research programme: gene therapies: Generation Bio
- DG 12P1: Deep genomics
- DPM-1001: Depymed Inc.
- VTX-801: Vivet therapeutics
- ALXN1840: Alexion/AstraZeneca
Wilson Disease Route of Administration
Wilson Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
Wilson Disease Molecule Type
Wilson Disease Products have been categorized under various Molecule types, such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Wilson Disease Pipeline Therapeutics Assessment
- Wilson Disease Assessment by Product Type
- Wilson Disease By Stage and Product Type
- Wilson Disease Assessment by Route of Administration
- Wilson Disease By Stage and Route of Administration
- Wilson Disease Assessment by Molecule Type
- Wilson Disease by Stage and Molecule Type
DelveInsight’s Wilson Disease Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Wilson Disease product details are provided in the report. Download the Wilson Disease pipeline report to learn more about the emerging Wilson Disease therapies
Some of the key companies in the Wilson Disease Therapeutics Market include:
Key companies developing therapies for Wilson Disease are – Vivet Therapeutics SAS, Alexion Pharmaceuticals Inc, ARBORMED Pharmaceuticals Inc, Deep Genomics Inc, DepYmed Inc, Enveda Biosciences Inc, Generation Bio Co, and Krisani Bio Sciences Pvt Ltd, and others.
Wilson Disease Pipeline Analysis:
The Wilson Disease pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Wilson Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wilson Disease Treatment.
- Wilson Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Wilson Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wilson Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Wilson Disease drugs and therapies
Wilson Disease Pipeline Market Drivers
- Increasing prevalence, rising demand for rapid diagnosis and better treatment, growing health awareness are some of the important factors that are fueling the Wilson Disease Market.
Wilson Disease Pipeline Market Barriers
- However, high cost of drugs, lack of reimbursement policies and other factors are creating obstacles in the Wilson Disease Market growth.
Scope of Wilson Disease Pipeline Drug Insight
- Coverage: Global
- Key Wilson Disease Companies: Generation Bio, Deep genomics, Depymed Inc., Vivet therapeutics, Alexion, AstraZeneca, and others
- Key Wilson Disease Therapies: Research programme: gene therapies, DG 12P1, DPM-1001, VTX-801, ALXN1840, and others
- Wilson Disease Therapeutic Assessment: Wilson Disease current marketed and Wilson Disease emerging therapies
- Wilson Disease Market Dynamics: Wilson Disease market drivers and Wilson Disease market barriers
Request for Sample PDF Report for Wilson Disease Pipeline Assessment and clinical trials
Table of Contents
1. Wilson Disease Report Introduction
2. Wilson Disease Executive Summary
3. Wilson Disease Overview
4. Wilson Disease- Analytical Perspective In-depth Commercial Assessment
5. Wilson Disease Pipeline Therapeutics
6. Wilson Disease Late Stage Products (Phase II/III)
7. Wilson Disease Mid Stage Products (Phase II)
8. Wilson Disease Early Stage Products (Phase I)
9. Wilson Disease Preclinical Stage Products
10. Wilson Disease Therapeutics Assessment
11. Wilson Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Wilson Disease Key Companies
14. Wilson Disease Key Products
15. Wilson Disease Unmet Needs
16 . Wilson Disease Market Drivers and Barriers
17. Wilson Disease Future Perspectives and Conclusion
18. Wilson Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services